Novartis wins legal battle over eye drops
A court in Germany has ruled in favour of the Swiss pharmaceutical company Novartis in a long-running legal case over the distribution of a drug to slow age-related vision loss.
Judges in Hamburg found the German company Aposan must not sell pre-filled syringes for €600 (CHF741) partly containing the Lucentis drug, said court officials on Tuesday.
The medication for the treatment of macular degeneration is distributed by Novartis in bottles of at a cost of €1,200. In the United States the drug is marketed by the Swiss pharmaceutical firm Roche.
Novartis said the verdict by the German court helped ensure patient safety. Worldwide sales of Lucentis totalled $2.4 billion in 2012.
Experts say the ruling could set a legal precedent for health insurance companies trying to cut rising drug prices.
The verdict is subject to an appeal.
See more Swissinfo articles in your Google results. Learn more
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.